Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio Group

10.96 EUR-0.18 %25.9, 11.55
14,602 following

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-0.18 %
-11.92 %
+3.39 %
-28.56 %
-41.57 %
-43.34 %
-37.43 %
-77.06 %
+588.88 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
461.38M EUR
Turnover
113.78K EUR
P/E (adj.) (26e)
16.46
EV/EBIT (adj.) (26e)
18.62
P/B (26e)
1.93
EV/S (26e)
2.99
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
16.50 EUR
Updated
23.09.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 23.09.2026

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
That was actually said tongue-in-cheek by Critter. OP messed up their own calculations with the wrong closing price. Quite sloppy carelessness from OP. Hopefully nobody sold this morning because of it.
9/22/2026, 8:26 AM
by Karhu Hylje
22
Here is a company report from Juha, largely inspired by the rights issue buzz :)\n\n> We are updating Revenio’s target price as the rights issue progresses. The subscription rights have now detached, which was reflected in the share price. We lowered our target price to EUR 16.5 ...
9/23/2026, 5:29 AM
by Sijoittaja-alokas
20
Reporting person: “After the share issue (annti), there will be about 42 million shares, so the share of new shares is about 31%” That subscription price (antihinta) being set so low is a strange pattern. It means very heavy dilution of holdings unless you put in significant new ...
yesterday
by Von Wangell
11
Congratulations to OP’s customers, their stocks are up much more today than anyone else’s.
9/22/2026, 8:29 AM
by JuhaK
10
[quote="Von_Wangell, post:3032, topic:1256"]\nn shares is about 42 million, so the share of new shares is about 31%'\n\nSetting the subscription price so low is a peculiar move. It means severe dilution for holdings unless you put in a significant amount of new money. How many retail...
yesterday
by Jepperson
5
I bought some myself at yesterday’s closing price of 13.12 per share. Just like everyone else who bought and sold at yesterday’s close. OP incorrectly calculated 10.99 based on their imagined closing price from yesterday, which would presumably lead to their current calculation of...
9/22/2026, 8:42 AM
by pottukoira
5
Kauppalehti does not take into account those 3 million euro issuance costs, which do not remain in the company’s value. In this particular case they are 3/80 million euros, so we are talking - in this very case - about a fairly marginal difference. In share issues of small companies...
9/22/2026, 8:27 AM
by Opa
5
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.11
2026

Interim report Q3'26

Revenio: The process has progressed to the rights issue
Research23.09.2026, 09.36 by
Juha Kinnunen

Revenio: The process has progressed to the rights issue

We update Revenio's target price following the detachment of subscription rights.

Revenio Group
Revenio: Subscription price fell short of expectations – Mechanical pressure on per-share figures
Analyst Comment22.09.2026, 08.23 by
Juha Kinnunen

Revenio: Subscription price fell short of expectations – Mechanical pressure on per-share figures

A lower-than-expected subscription price of EUR 6.19 increases the number of shares and exerts mechanical pressure on per-share estimates.

Revenio Group
Regulatory press release21.09.2026, 16.00

Managers' transactions - Bill Östman

Revenio Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release21.09.2026, 16.00

Managers' transactions - Heli Lindfors

Revenio Group
Regulatory press release21.09.2026, 16.00

Managers' transactions - Arne Boye Nielsen

Revenio Group
Regulatory press release21.09.2026, 16.00

Managers' transactions - Anat Loewenstein

Revenio Group
Regulatory press release21.09.2026, 16.00

Managers' transactions - Marc Abitbol

Revenio Group
Regulatory press release21.09.2026, 16.00

Changes in Revenio Group Corporation's own shares

Revenio Group
Regulatory press release21.09.2026, 16.00

Managers' transactions - Nicklas Hansen

Revenio Group
Regulatory press release21.09.2026, 16.00

Managers' transactions - Charles Vilgrain

Revenio Group
Regulatory press release21.09.2026, 11.30

INSIDE INFORMATION: Revenio Group Corporation announces the terms and conditions of its fully underwritten rights offering of approximately EUR 80 million

Revenio Group
Revenio's Capital Markets Day: The picture became clearer but not much brighter
Analyst Comment16.09.2026, 13.20 by
Juha Kinnunen

Revenio's Capital Markets Day: The picture became clearer but not much brighter

The integration process is likely to take longer than anticipated, as the company is implementing significant measures still in 2028.

Revenio Group
Revenio Group Capital Markets Day 2026
Webcast15.09.2026, 13.00

Revenio Group Capital Markets Day 2026

At the Capital Markets Day, the company's key personnel will present an in-depth overview of Revenio's strategy.

Revenio Group
Regulatory press release15.09.2026, 08.00

Revenio updates its strategy for 2027–2029 and provides new financial targets for the strategy period

Revenio Group
Regulatory press release14.09.2026, 15.30

Composition of Revenio’s Shareholders’ Nomination Board

Revenio Group
Revenio: New iCare IC1000 strengthens core business competitiveness
Analyst Comment10.09.2026, 10.58 by
Juha Kinnunen

Revenio: New iCare IC1000 strengthens core business competitiveness

The digital solutions of the new iCare IC1000 tonometer strengthen the company's core business.

Revenio Group
Press release10.09.2026, 08.00

iCare IC1000™: Precision Made Effortless

Revenio Group
Revenio Q2'26: Vision to become clearer toward the end of the year
Research09.09.2026, 10.55 by
Juha Kinnunen

Revenio Q2'26: Vision to become clearer toward the end of the year

Revenio's Q2 result fell short of our expectations due to a weak period in the core business. Visionix performed roughly as expected in its debut, and its integration appears to be progressing as planned.

Revenio Group
Revenio, Audiocast, Q2'26
Webcast08.09.2026, 14.00

Revenio, Audiocast, Q2'26

Revenio Group
Regulatory press release08.09.2026, 08.00

Revenio Group Corporation: Half-Year Report January 1 – June 30, 2026

Revenio Group